The trial was assessing the efficacy of a fixed-dose combination of nivolumab and relatlimab in patients with microsatellite stable metastatic colorectal cancer whose disease has progressed after one to four prior lines of therapy.
Bristol Myers Squibb noted the trial’s cancellation was not due to safety concerns and said it will continue exploring the combination therapy as a potential treatment for other tumor types.
The drugmaker will also share data with investigators so they can determine next steps for patients currently enrolled in the trial.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.